Krystal Biotech to Present at H.C. Wainwright 26th Annual Global Investment Conference
06 Septembre 2024 - 1:00PM
Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a
commercial-stage biotechnology company, today announced that the
Company will participate in the H.C. Wainwright 26th Annual Global
Investment Conference on September 10, 2024, in New York. Krish S.
Krishnan, Chairman and Chief Executive Officer, is scheduled to
give a company presentation at 12:30 pm ET and host investor
meetings throughout the day.
A webcast of the presentation will be available
here beginning at 12:30 pm ET on Tuesday, September 10, 2024 and
will be posted on the Investors section of the Company’s
website.
About Krystal Biotech, Inc.
Krystal Biotech, Inc. (NASDAQ: KRYS) is a commercial-stage
biotechnology company focused on the discovery, development and
commercialization of genetic medicines to treat diseases with high
unmet medical needs. VYJUVEK® is the Company’s first commercial
product, the first-ever redosable gene therapy, and the first
medicine approved by the FDA for the treatment of dystrophic
epidermolysis bullosa. The Company is rapidly advancing a robust
preclinical and clinical pipeline of investigational genetic
medicines in respiratory, oncology, dermatology, ophthalmology, and
aesthetics. Krystal Biotech is headquartered in Pittsburgh,
Pennsylvania. For more information, please visit
http://www.krystalbio.com, and follow @KrystalBiotech on LinkedIn
and X (formerly Twitter).
CONTACTInvestors and
Media:Stéphane PaquetteKrystal
Biotechspaquette@krystalbio.com
Krystal Biotech (NASDAQ:KRYS)
Graphique Historique de l'Action
De Sept 2024 à Oct 2024
Krystal Biotech (NASDAQ:KRYS)
Graphique Historique de l'Action
De Oct 2023 à Oct 2024